share_log

Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $100 Price Target

Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $100 Price Target

Needham重申买入intra-cellular therapies,在维持100美元的目标股价。
Benzinga ·  2024/10/30 20:17  · 评级/大行评级

Needham analyst Ami Fadia reiterates Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and maintains $100 price target.

Needham的分析师Ami Fadia重申买入Intra-Cellular Therapies (纳斯达克: ITCI),并维持100美元的价格目标。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发